Live from the NIH registry
Studies recruiting near Rancho Cucamonga right now
Top 25 of 1,487 recruiting studies, sorted by proximity — each links to its official registry page
Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
Von Willebrand Disease, Type 3, Concomitant VWD and Hemophilia
Phase 1
Interventional 40 participants sought
The Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders (CIBD) — Orange, California (28.5 mi)
· Sponsor: Bleeding and Clotting Disorders Institute Peoria, Illinois
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
Phase 2
Interventional 222 participants sought
Loma Linda University Medical Center — Loma Linda, California (18.3 mi)
· Sponsor: National Cancer Institute (NCI)
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Lymphoma, Large B-Cell, Diffuse
Phase 2
Interventional 594 participants sought
City of Hope Comprehensive Cancer Center ( Site 0191) — Duarte, California (23.5 mi)
· Sponsor: Merck Sharp & Dohme LLC
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PIK3CA Mutation, HER2- Negative Breast Cancer
Phase 3
Interventional 540 participants sought
City of Hope National Medical Center — Duarte, California (23.5 mi)
· Sponsor: Relay Therapeutics, Inc.
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
Primary Membranous Nephropathy
Phase 2
Interventional 30 participants sought
Research Site — Loma Linda, California (18.3 mi)
· Sponsor: Alexion Pharmaceuticals, Inc.
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
N/A
Interventional 400 participants sought
Loma Linda University Medical Center — Loma Linda, California (18.3 mi)
· Sponsor: Medtronic MiniMed, Inc.
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated
Diabetic Macular Edema
Phase 1, Phase 2
Interventional 49 participants sought
Win Retina — Arcadia, California (26.8 mi)
· Sponsor: Boehringer Ingelheim
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Carcinoma, Non-Small-Cell Lung
Phase 1, Phase 2
Interventional 450 participants sought
City of Hope ( Site 0014) — Duarte, California (23.5 mi)
· Sponsor: Merck Sharp & Dohme LLC
Shorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue Infections
Necrotizing Soft Tissue Infection
N/A
Observational 50 participants sought
University of California Irvine Medical Center — Orange, California (28.5 mi)
· Sponsor: University of California, Irvine
A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
Advanced Cancer, Solid Tumor
Phase 1
Interventional 26 participants sought
City of Hope National Medical Center — Duarte, California (23.5 mi)
· Sponsor: Proviva Therapeutics, Inc.
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Endometrial Cancer
Phase 3
Interventional 600 participants sought
Research Site — Duarte, California (23.5 mi)
· Sponsor: AstraZeneca
Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
Age-Related Macular Degeneration, Geographic Atrophy
N/A
Interventional 125 participants sought
Loma Linda University — Loma Linda, California (18.3 mi)
· Sponsor: VisionCare, Inc.
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Phase 1
Interventional 15 participants sought
City of Hope Medical Center — Duarte, California (23.5 mi)
· Sponsor: City of Hope Medical Center
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Phase 2
Interventional 120 participants sought
University of California Irvine — Orange, California (28.5 mi)
· Sponsor: Regeneron Pharmaceuticals
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL)
Phase 1
Interventional 106 participants sought
City of Hope — Duarte, California (23.5 mi)
· Sponsor: Umoja Biopharma
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis
Phase 2
Interventional 168 participants sought
North America Research Institute — San Dimas, California (13.8 mi)
· Sponsor: R1 Therapeutics
Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
Breast Carcinoma, Chemotherapy-Induced Peripheral Neuropathy
Phase 2
Interventional 120 participants sought
City of Hope Medical Center — Duarte, California (23.5 mi)
· Sponsor: City of Hope Medical Center
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
MTAP-deleted Solid Tumors
Phase 1, Phase 2
Interventional 450 participants sought
City of Hope - Duarte Cancer Center — Duarte, California (23.5 mi)
· Sponsor: Bayer
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
City of Hope Upland — Upland, California (5.0 mi)
· Sponsor: SWOG Cancer Research Network
Stage II/III Colorectal Cancer Recurrence
Colorectal Cancer, Colorectal Adenocarcinoma
N/A
Observational 400 participants sought
City of Hope Medical Center — Monrovia, California (24.8 mi)
· Sponsor: City of Hope Medical Center
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Solid Tumor, Adult, Metastatic Breast Cancer
Phase 1
Interventional 392 participants sought
City of Hope Comprehensive Cancer Center — Duarte, California (23.5 mi)
· Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Phase 4
Interventional 6,000 participants sought
Riverside Community Hospital — Riverside, California (15.3 mi)
· Sponsor: Duke University
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Urothelial Cancer, Bladder Cancer
Phase 2, Phase 3
Interventional 630 participants sought
Research Site — Fullerton, California (27.0 mi)
· Sponsor: Daiichi Sankyo
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
Phase 3
Interventional 450 participants sought
University of California, Irvine (UCI) Health - UC Irvine Medical Center — Orange, California (28.5 mi)
· Sponsor: Eli Lilly and Company
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Renal Cell Carcinoma
Phase 3
Interventional 904 participants sought
Providence Medical Foundation ( Site 0141) — Fullerton, California (27.0 mi)
· Sponsor: Merck Sharp & Dohme LLC